You are here

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer

Authors

  • Hiroyuki Arai Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Yi Xiao Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Fotios Loupakis Clinical and Experimental Oncology Department, Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy PubMed articlesGoogle scholar articles
  • Natsuko Kawanishi Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Jingyuan Wang Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Francesca Battaglin Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Shivani Soni Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Wu Zhang Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Christoph Mancao Oncology Biomarker Development, Genentech Inc, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Bodour Salhia Department of Translational Genomics, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Shannon M Mumenthaler Lawrence J. Ellison Institute for Transformative Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Daniel J Weisenberger Department of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Gangning Liang Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Chiara Cremolini Department of Translational Medicine, Division of Medical Oncology, University of Pisa, Pisa, Italy PubMed articlesGoogle scholar articles
  • Alfredo Falcone Department of Translational Medicine, Division of Medical Oncology, University of Pisa, Pisa, Italy PubMed articlesGoogle scholar articles
  • Joshua Millstein Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles
  • Heinz-Josef Lenz Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA PubMed articlesGoogle scholar articles

Citation

Arai H, Xiao Y, Loupakis F, et al
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer
Journal for ImmunoTherapy of Cancer 2020;8:e001714. doi: 10.1136/jitc-2020-001714
Online issue publication 
November 10, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.